In the shadowed caves of ancient India, Siddhartha Gautama sat under a bodhi tree, wrestling with the hydra-headed beast of ...

Mounjaro - the brand name for tirzepatide - has become one of the most talked-about medications in metabolic health, and for good reason. But the conversation around it has gotten tangled up with ...

Brianna LaPaglia issues a candid message about Ozempic after saying she knows several people who use the drug and don't need it ...

Eli Lilly plans to ​invest $3 billion over ‌the next decade to expand supply ​chain capacity in ​China and build production ⁠capacity for ​type-2 diabetes and obesity ​treatment orforglipron, the ...

The results of this obesity medication are literally eye-popping. A new review of adverse effects reports to the FDA between the years 2017 and 2024 reveals that Ozempic and Wegovy have both been ...

The investment in China follows similar outlays by the drugmaker in other regions as it prepares for high orforglipron demand.

And 3 times higher in men than in women, analysis of unintended side effect reports shows Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of 'eye stroke' (ischaemic optic ...

A venture-backed healthcare startup wants to fix how employers pay for GLP-1s — without touching insurance. Andel launched its direct-to-employer medication platform Wednesday, backed by $4.5 million ...

The TikToker revealed that she could "lose a couple" if she did Ozempic, but refuses to indulge.

WASHINGTON (dpa-AFX) - A large-scale study has found that patients taking Wegovy may face a significantly higher risk of sudden vision loss compared with those using Ozempic. Researchers reported that ...

GLP-1 obesity treatments may see wider access as key patents lapse.

When fresh data appeared in the British Medical Journal in early 2026, it confirmed a suspicion that physicians had long harbored. Patients who discontinue ...